Stocks That Hit 52-Week Lows On Friday
During Friday's trading, 69 companies set new 52-week lows.
Chardan Capital Maintains Buy on BiomX, Lowers Price Target to $6
Chardan Capital analyst Keay Nakae maintains BiomX (AMEX:PHGE) with a Buy and lowers the price target from $10 to $6.
The Daily Biotech Pulse: INmune Bio’s Planned Alzheimer’s Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours:
BiomX Announces Publication In The Journal, Bioinformatics
BiomX Announces Publication in the Journal, Bioinformatics
Development of Exodus Algorithm Overcomes Limitations in Identifying and Quantifying the Genomes of Genetically Related Microorganisms
BiomX Inc. (NYSE:PHGE)
Ladenburg Thalmann Maintains Buy on BiomX, Lowers Price Target to $8
Ladenburg Thalmann analyst Michael Higgins maintains BiomX (AMEX:PHGE) with a Buy and lowers the price target from $13 to $8.
Earnings Scheduled For May 11, 2022
Companies Reporting Before The Bell
• Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.
